Genetically Modulated Substrate Reduction Therapy for Sanfilippo syndrome – proof of principle

Introduction: Sanfilippo syndrome, or Mucopolysaccharidosis (MPS) type III refers to a group of five autosomal recessive neurodegenerative lysosomal storage disorders caused by the incomplete lysosomal degradation of the glycosaminoglycan (GAG) heparan sulphate (HS) that accumulates in patient cells...

ver descrição completa

Detalhes bibliográficos
Autor principal: Santos, Juliana Inês (author)
Outros Autores: Coutinho, Maria Francisca (author), Alves, Sandra (author)
Formato: conferenceObject
Idioma:eng
Publicado em: 2018
Assuntos:
Mucopolysaccharidosis (MPS)
Mucopolissacaridoses
RNAi
Terapia de Redução do Substrato
Síndrome de Sanfilippo
Doenças Genéticas
Texto completo:http://hdl.handle.net/10400.18/5514
País:Portugal
Oai:oai:repositorio.insa.pt:10400.18/5514

Texto Completo

http://hdl.handle.net/10400.18/5514

Registos relacionados